
GeoVax Advances Mpox/Smallpox Vaccine Toward Phase 3 Trial Amid Global Supply Concerns
GeoVax Labs is preparing to initiate a pivotal Phase 3 trial for its GEO-MVA vaccine targeting mpox and smallpox in the second half of 2026, addressing critical global supply constraints and biosecurity needs while reporting reduced financial losses for 2025.
Read full story






















